Pathophysiology News and Research

RSS

Study: Male and female differences in fear memory is attributed to Cdk5 gene

In a mouse model of traumatic memory, male mice recall fear-related memories better than female mice, according to a study in Biological Psychiatry. The difference between sexes was attributed to a gene important for creating fear memories and stress behavior, called cyclin dependent kinase 5, which was naturally activated in male but not in female mice.

18 Jan 2019

First international consensus on the diagnosis and management of fibromuscular dysplasia

The "First international consensus on the diagnosis and management of fibromuscular dysplasia" (FMD) has been published online first today in Vascular Medicine and the Journal of Hypertension.

17 Jan 2019

Alzheimer's pathophysiology shows racial disparities

A study has identified racial disparities between African-Americans and Caucasians in the way in which Alzheimer’s disease arises and develops.

7 Jan 2019

Alterations in brain networks contribute to cognitive dysfunction in psychiatric disorders

Psychiatric disorders share common alterations of functional connectivity between three core brain networks involved in cognition, according to a meta-analysis published in Biological Psychiatry.

3 Jan 2019

Scientists develop new stem cell line to study conversion of stem cells into muscle

To help patients with muscle disorders, scientists at The University of Texas Health Science Center at Houston (UTHealth) have engineered a new stem cell line to study the conversion of stem cells into muscle. Findings appeared in Cell Reports.

13 Dec 2018

Brazilian professors propose guidelines for therapeutic use of melatonin

Sixty years after melatonin was isolated and with more than 23,000 published studies showing the many functions of this hormone secreted by the pineal gland, guidelines should be discussed and established for its therapeutic use.

11 Dec 2018

Eliminating microglia can reverse some aspects of stress sensitization, study shows

Using an animal model of chronic stress, researchers at The Ohio State University have shown that the immune cells of the brain, called microglia, hold unique signatures of chronic stress that leave the animal more sensitive to future stressful experiences, evident by increased anxiety and immune responses.

4 Dec 2018

Researchers identify potential nutritional alternative for people with fish allergy

Fish allergy is one of the most dangerous food allergies, as it is often associated with potentially life-threatening symptoms such as anaphylactic shock.

30 Nov 2018

Discovery would help specify role of genetics in the development of neuropsychiatric disorders

Neurobiologists from I.M. Sechenov First Moscow State Medical University confirmed that stress in early age affects the mice with activated and deactivated CDH13 gene in different ways.

27 Nov 2018

Forming 3D Neuronal Models of the Brain

In this interview, conducted at SfN 2018, Grischa Chandy from Molecular Devices provides insight on 3D imaging solutions for neuroscience research.

From Molecular Devices, LLC 19 Nov 2018

New multi-allergen test works just as well with dried blood

Using the Allergy Chip co-developed by MedUni Vienna, sensitization to allergens can be detected early on. This normally requires a doctor taking a blood sample for subsequent analysis in a laboratory equipped with the Chip.

8 Nov 2018

New findings highlight importance of inflammatory component in atherosclerosis pathogenesis

One of the main characteristics of atherosclerosis is the accumulation of lipids in the intimal layer of the arterial wall.

29 Oct 2018

Quadrant Biosciences announces collaboration on research into treatment of ASD

Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.

26 Oct 2018

Researchers use MRI to watch how electrical stimulation could cure gastrointestinal disorders

More than 60 million people in the U.S. suffer from disorders in the gastrointestinal tract that could be cured by electrical stimulation, but scientists don't fully understand the therapy's effects on a critical organ: the stomach.

25 Oct 2018

Bioengineering scientists propose new paradigm for research into cardiovascular diseases

Thrombosis-on-a-chip, vasculature-on-a-chip and engineered models of human cardiac fibrosis are just a few of the new technologies revolutionizing research into human cardiovascular disease--a condition responsible for 17 million deaths per annum globally.

25 Oct 2018

Study examines factors associated with fasting hyperglucagonemia in type 2 diabetes

A new study examined the relationship between fasting hyperglucagonemia -- which can negatively affect glucose metabolism in patients with type 2 diabetes -- and several biochemical and glycemic factors in subjects with T2D or in a nondiabetic control group.

24 Oct 2018

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor.

7 Oct 2018

Study analyzes distribution of two cytokines in sections of carotid atherosclerotic plaques

Inflammation is currently a well-documented component of atheroslcerosis pathogenesis, which plays a role at each stage of the disease development.

6 Oct 2018

Study reveals factors linked to the development of Crohn's disease

How cells talk to each other, and what they say, has long held fascination for Seema Khurana, professor of biology and biochemistry.

5 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018